AMGEN INC — Director's Dealing 2021

Nov 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMGEN INC (AMGN)
CIK: 0000318154
Period of Report: 2021-11-05

Reporting Person: Louie Linda H. (VP, Finance & CAO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-05	Common Stock	A	350	—	Acquired	8647	Direct

Footnotes

F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in two annual installments of 50% on 11/5/2022 and 11/5/2023, respectively.

F2: These shares include the following RSUs granted under the Company's equity plans: 58 RSUs which will vest on 4/27/2022; 132 RSUs which vest in installments of 65 on 5/3/2022 and 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024; 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; and 350 RSUs which will vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3: These shares include 73 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.